化膿性汗腺炎の世界市場レポート 2025年

化膿性汗腺炎の市場規模は、今後数年間で力強い成長が見込まれます。2029年には年間平均成長率（CAGR）7.0％で16億3,000万米ドルに成長します。予測期間の成長は、生物学的療法の開発、プレシジョン・メディシン・アプローチ、臨床試験の拡大、世界な取り組みと資金調達、ヘルスケア政策支援に起因します。予測期間の主な動向には、先進免疫調節療法、遠隔医療と遠隔モニタリング、患者中心のケア、低侵襲外科的介入、個別化されたライフスタイルの推奨などが含まれます。

皮膚疾患の有病率の増加が今後の化膿性汗腺炎市場の成長を牽引すると予想されます。皮膚疾患には、細菌感染、ウイルス感染、真菌感染、アレルギー反応、皮膚がん、寄生虫によるものなど、さまざまな問題が含まれます。慢性的で重篤な皮膚疾患である化膿性汗腺炎（HS）は、認知度の向上、正確な診断、患者数の増加、研究の進歩により、その管理のための新製品やサービスの開発を促しています。例えば、2024年1月、米国を拠点とするがん撲滅に焦点を当てた非営利団体である米国がん協会（American Cancer Society）は、2023年に記録された104,930例から3.2％増となる108,270例の皮膚がんが報告されると予測しています。このように、皮膚疾患の有病率の上昇が化膿性汗腺炎市場の成長を牽引しています。

ヘルスケア支出の増加は、今後の化膿性汗腺炎市場拡大のカタリストとなります。ヘルスケア支出には、家族計画、栄養、緊急支援など、健康に主眼を置いたヘルスケアサービスの提供に関連するすべての費用が含まれます。ヘルスケア支出の増加は、包括的な患者支援プログラムの確立を促進し、化膿性汗腺炎の管理改善を促進し、この領域のケアと研究の質にプラスの影響を与えます。例えば、メディケア＆メディケイド・サービスセンターが2022年3月に発表した2021-2030年国民医療費（NHE）報告書によると、国民医療費は2021年から2030年にかけて年平均5.1％増加し、2030年には約6兆8,000億米ドルに達すると予測されています。その結果、医療支出の増大が化膿性汗腺炎市場の成長軌道を後押しすることになります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の化膿性汗腺炎PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の化膿性汗腺炎市場：成長率分析
• 世界の化膿性汗腺炎市場の実績：規模と成長, 2019-2024
• 世界の化膿性汗腺炎市場の予測：規模と成長, 2024-2029, 2034F
• 世界の化膿性汗腺炎総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の化膿性汗腺炎市場肌の状態別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 毛包炎
• ニキビ
• 毛嚢炎
• 深部面皰
• 世界の化膿性汗腺炎市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 錠剤
• 静脈内（IV）注射
• 世界の化膿性汗腺炎市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口
• 非経口
• 世界の化膿性汗腺炎市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 医薬品
• 手術
• 光線力学療法（PDT）
• レーザー治療
• その他の治療法
• 世界の化膿性汗腺炎市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• 在宅ケア
• その他のエンドユーザー
• 世界の化膿性汗腺炎市場、タイプ別サブセグメンテーション：毛包炎の種類によるサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 急性毛包炎
• 慢性毛包炎
• 世界の化膿性汗腺炎市場、タイプ別サブセグメンテーション：ニキビの種類別の分類、実績と予測, 2019-2024, 2024-2029F, 2034F
• 非炎症性ニキビ
• 炎症性ニキビ
• 世界の化膿性汗腺炎市場、タイプ別サブセグメンテーション：毛嚢炎のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 単発性毛嚢炎
• 再発性毛嚢炎
• 世界の化膿性汗腺炎市場、タイプ別サブセグメンテーション：深部面皰のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 嚢胞
• 結節

第7章 地域別・国別分析

• 世界の化膿性汗腺炎市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の化膿性汗腺炎市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 化膿性汗腺炎市場：競合情勢
• 化膿性汗腺炎市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Eli Lilly and Co Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• UCB S.A.
• Leo Pharma A/S
• Almirall S.A.
• Acelyrin Inc.
• AnaptysBio Inc.
• Arcutis Biotherapeutics Inc.
• Otsuka Pharmaceutical Co. Ltd.
• Yamo Pharmaceuticals
• Bayer AG
• AstraZeneca plc
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma
• Chemocentryx
• Priovant Therapeutics
• Aristea Therapeutics

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 化膿性汗腺炎市場2029：新たな機会を提供する国
• 化膿性汗腺炎市場2029：新たな機会を提供するセグメント
• 化膿性汗腺炎市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Hidradenitis suppurativa (HS) is a chronic skin condition characterized by the development of painful lumps deep within the skin, typically occurring in areas where skin rubs against skin, such as the armpits, inner thighs, and groin. These lumps can lead to the formation of abscesses and tunnels beneath the skin.

Various skin conditions associated with hidradenitis suppurativa include folliculitis, pimples, boils, and deep acne. Folliculitis, a common skin condition, arises when hair follicles become inflamed or infected. Treatments for folliculitis encompass creams, pills, and procedures such as laser hair removal. The products utilized for hidradenitis suppurativa treatment include tablets and intravenous (IV) injections, administered through oral and parenteral routes. Treatment modalities involve medications, surgical interventions, photodynamic therapy (PDT), laser treatment, among others. End-users of these treatments include hospitals, specialty clinics, homecare settings, and others.

The hidradenitis suppurativa (HS) research report is one of a series of new reports from The Business Research Company that provides hidradenitis suppurativa (HS) market statistics, including the hidradenitis suppurativa (HS) industry's global market size, regional shares, competitors with an hidradenitis suppurativa (HS) market share, detailed hidradenitis suppurativa (HS) market segments, market trends and opportunities, and any further data you may need to thrive in the hidradenitis suppurativa (HS) industry. This hidradenitis suppurativa (HS) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The hidradenitis suppurativa market size has grown strongly in recent years. It will grow from $1.16 billion in 2024 to $1.25 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to increased diagnosis awareness, limited treatment options, advancements in dermatology, rising disease prevalence, patient advocacy initiatives

The hidradenitis suppurativa market size is expected to see strong growth in the next few years. It will grow to $1.63 billion in 2029 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to biologic therapies development, precision medicine approaches, clinical trial expansion, global initiatives and funding, healthcare policy support. Major trends in the forecast period include advanced immunomodulatory therapies, telemedicine and remote monitoring, patient-centric care, minimally invasive surgical interventions, personalized lifestyle recommendations.

The increasing prevalence of skin diseases is expected to drive the growth of the hidradenitis suppurativa market moving forward. Skin diseases encompass a wide range of issues, including those caused by bacterial, viral, and fungal infections, allergic reactions, skin cancers, and parasites. Hidradenitis suppurativa (HS), a chronic and severe skin condition, is prompting the development of new products and services for its management due to heightened awareness, accurate diagnosis, a growing patient population, and advancements in research. For instance, in January 2024, the American Cancer Society, a U.S.-based non-profit organization focused on cancer elimination, projected 108,270 reported cases of skin cancer, marking a 3.2% increase from the 104,930 cases recorded in 2023. Thus, the rise in skin disease prevalence is driving the growth of the hidradenitis suppurativa market.

The upswing in healthcare expenditure serves as a catalyst for the expansion of the hidradenitis suppurativa market in the future. Healthcare expenditure encompasses all costs associated with providing health services, including aspects such as family planning, nutrition, and emergency assistance with a primary focus on health. Increased healthcare spending facilitates the establishment of comprehensive patient support programs, fostering improved management of hidradenitis suppurativa and positively impacting the quality of care and research in this domain. For instance, according to the 2021-2030 National Health Expenditure (NHE) report by the Centers for Medicare & Medicaid Services in March 2022, national health spending is anticipated to rise by an average of 5.1% annually between 2021 and 2030, projected to reach around $6.8 trillion by 2030. Consequently, the escalation in healthcare expenditure fuels the growth trajectory of the hidradenitis suppurativa market.

The increasing adoption of biologics stands as a prominent trend within the hidradenitis suppurativa market. Leading companies in this sector are heavily investing in research and development endeavors, resulting in the approval of biologic therapies specifically designed for managing hidradenitis suppurativa, thereby solidifying their market position. For example, in June 2023, Novartis AG, a Switzerland-based pharmaceutical company, received approval from the European regulatory authority for Cosentyx, a groundbreaking biologic therapy targeting hidradenitis suppurativa. Cosentyx represents a fully human biologic that effectively inhibits interleukin-17A, a pivotal cytokine associated with the disease. Having undergone clinical research for over 14 years, Cosentyx has established itself as a well-researched medication catering to hidradenitis suppurativa.

Strategic partnerships emerge as a significant trend gaining traction within the hidradenitis suppurativa market. Key industry players are proactively forging strategic alliances to fortify their market positions. For instance, in June 2023, Novartis, a Switzerland-based pharmaceutical company, entered into a partnership with the Emirates Dermatology Society (EDS), based in the UAE, aimed at advancing Hidradenitis Suppurativa awareness within the UAE region. The collaboration's objectives extend to providing crucial insights that aid healthcare providers and policymakers in supporting individuals grappling with this debilitating disease. Novartis and EDS are slated to establish scientific and educational platforms targeting dermatologists and patients within the UAE, fostering awareness and understanding. Furthermore, both organizations are committed to leveraging Real World Evidence (RWE) to capture and generate localized data on hidradenitis suppurativa.

In October 2022, Amgen Inc., a leading biopharmaceutical company based in the United States, successfully acquired ChemoCentryx Inc. for a substantial amount of $3.7 billion. This strategic acquisition allows Amgen to strengthen its market position by incorporating ChemoCentryx's product, TAVNEOS, into its diverse portfolio. TAVNEOS, an FDA-approved complement 5a receptor inhibitor with gastrointestinal restriction, holds significant potential as a complementary therapy for individuals affected by hidradenitis suppurativa. ChemoCentryx Inc. specializes in the development of pharmaceuticals targeting autoimmune and oncology diseases, including conditions such as hidradenitis suppurativa.

Major companies operating in the hidradenitis suppurativa market include Pfizer Inc., Johnson & Johnson, AbbVie Inc., Novartis AG, Eli Lilly and Co Ltd., UCB S.A., Leo Pharma A/S, Almirall S.A., Acelyrin Inc., AnaptysBio Inc., Arcutis Biotherapeutics Inc., Otsuka Pharmaceutical Co. Ltd., Yamo Pharmaceuticals, Bayer AG, AstraZeneca plc, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Chemocentryx, Priovant Therapeutics, Aristea Therapeutics, Samsung Bioepis, Organon, Union Therapeutics, Revance Therapeutics, Dermavant Sciences, Dermira Inc., MedImmune LLC, Taro Pharmaceutical Industries Ltd., Immunic Inc.

North America was the largest region in the hidradenitis suppurativa market in 2024. The regions covered in the hidradenitis suppurativa market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the hidradenitis suppurativa market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The hidradenitis suppurativa (HS) market consists of revenues earned by entities providing treatment to axillary-mammary-inguinal hidradenitis suppurativa, follicular hidradenitis suppurativa, gluteal hidradenitis suppurativa, and syndromic hidradenitis suppurativa. The market value includes the value of related goods sold by the service provider or included within the service offering. The hidradenitis suppurativa (HS) market also includes sales of surgery biologics, antibiotics, immunosuppressive drugs, zinc supplements, and retinoids. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hidradenitis Suppurativa Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hidradenitis suppurativa market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hidradenitis suppurativa ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hidradenitis suppurativa market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Skin Condition: Folliculitis; Pimples; Boils; Deep-Acne
• 2) By Product: Tablet; Intravenous (IV) Injection
• 3) By Route Of Administration: Oral; Parenteral
• 4) By Treatment: Medications; Surgery; Photodynamic Therapy (PDT); Laser Treatment; Other Treatments
• 5) By End User: Hospital; Specialty Clinic; Homecare; Other End Users
• Subsegments:
• 1) By Folliculitis: Acute Folliculitis; Chronic Folliculitis
• 2) By Pimples: Non-Inflammatory Pimples; Inflammatory Pimples
• 3) By Boils: Single Boil; Recurrent Boils
• 4) By Deep-Acne: Cysts; Nodules
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; AbbVie Inc.; Novartis AG; Eli Lilly and Co Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Hidradenitis Suppurativa Market Characteristics

3. Hidradenitis Suppurativa Market Trends And Strategies

4. Hidradenitis Suppurativa Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Hidradenitis Suppurativa Growth Analysis And Strategic Analysis Framework

• 5.1. Global Hidradenitis Suppurativa PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Hidradenitis Suppurativa Market Growth Rate Analysis
• 5.4. Global Hidradenitis Suppurativa Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Hidradenitis Suppurativa Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Hidradenitis Suppurativa Total Addressable Market (TAM)

6. Hidradenitis Suppurativa Market Segmentation

• 6.1. Global Hidradenitis Suppurativa Market, Segmentation By Skin Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Folliculitis
• Pimples
• Boils
• Deep-Acne
• 6.2. Global Hidradenitis Suppurativa Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tablet
• Intravenous (IV) Injection
• 6.3. Global Hidradenitis Suppurativa Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• 6.4. Global Hidradenitis Suppurativa Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medications
• Surgery
• Photodynamic Therapy (PDT)
• Laser Treatment
• Other Treatments
• 6.5. Global Hidradenitis Suppurativa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Specialty Clinic
• Homecare
• Other End Users
• 6.6. Global Hidradenitis Suppurativa Market, Sub-Segmentation Of Folliculitis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Folliculitis
• Chronic Folliculitis
• 6.7. Global Hidradenitis Suppurativa Market, Sub-Segmentation Of Pimples, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Non-Inflammatory Pimples
• Inflammatory Pimples
• 6.8. Global Hidradenitis Suppurativa Market, Sub-Segmentation Of Boils, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Single Boil
• Recurrent Boils
• 6.9. Global Hidradenitis Suppurativa Market, Sub-Segmentation Of Deep-Acne, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cysts
• Nodules

7. Hidradenitis Suppurativa Market Regional And Country Analysis

• 7.1. Global Hidradenitis Suppurativa Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Hidradenitis Suppurativa Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hidradenitis Suppurativa Market

• 8.1. Asia-Pacific Hidradenitis Suppurativa Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Hidradenitis Suppurativa Market, Segmentation By Skin Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Hidradenitis Suppurativa Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Hidradenitis Suppurativa Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hidradenitis Suppurativa Market

• 9.1. China Hidradenitis Suppurativa Market Overview
• 9.2. China Hidradenitis Suppurativa Market, Segmentation By Skin Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Hidradenitis Suppurativa Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Hidradenitis Suppurativa Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hidradenitis Suppurativa Market

• 10.1. India Hidradenitis Suppurativa Market, Segmentation By Skin Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Hidradenitis Suppurativa Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Hidradenitis Suppurativa Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hidradenitis Suppurativa Market

• 11.1. Japan Hidradenitis Suppurativa Market Overview
• 11.2. Japan Hidradenitis Suppurativa Market, Segmentation By Skin Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Hidradenitis Suppurativa Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Hidradenitis Suppurativa Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hidradenitis Suppurativa Market

• 12.1. Australia Hidradenitis Suppurativa Market, Segmentation By Skin Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Hidradenitis Suppurativa Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Hidradenitis Suppurativa Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hidradenitis Suppurativa Market

• 13.1. Indonesia Hidradenitis Suppurativa Market, Segmentation By Skin Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Hidradenitis Suppurativa Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Hidradenitis Suppurativa Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hidradenitis Suppurativa Market

• 14.1. South Korea Hidradenitis Suppurativa Market Overview
• 14.2. South Korea Hidradenitis Suppurativa Market, Segmentation By Skin Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Hidradenitis Suppurativa Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Hidradenitis Suppurativa Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hidradenitis Suppurativa Market

• 15.1. Western Europe Hidradenitis Suppurativa Market Overview
• 15.2. Western Europe Hidradenitis Suppurativa Market, Segmentation By Skin Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Hidradenitis Suppurativa Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Hidradenitis Suppurativa Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hidradenitis Suppurativa Market

• 16.1. UK Hidradenitis Suppurativa Market, Segmentation By Skin Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Hidradenitis Suppurativa Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Hidradenitis Suppurativa Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hidradenitis Suppurativa Market

• 17.1. Germany Hidradenitis Suppurativa Market, Segmentation By Skin Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Hidradenitis Suppurativa Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Hidradenitis Suppurativa Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hidradenitis Suppurativa Market

• 18.1. France Hidradenitis Suppurativa Market, Segmentation By Skin Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Hidradenitis Suppurativa Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Hidradenitis Suppurativa Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hidradenitis Suppurativa Market

• 19.1. Italy Hidradenitis Suppurativa Market, Segmentation By Skin Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Hidradenitis Suppurativa Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Hidradenitis Suppurativa Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hidradenitis Suppurativa Market

• 20.1. Spain Hidradenitis Suppurativa Market, Segmentation By Skin Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Hidradenitis Suppurativa Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Hidradenitis Suppurativa Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hidradenitis Suppurativa Market

• 21.1. Eastern Europe Hidradenitis Suppurativa Market Overview
• 21.2. Eastern Europe Hidradenitis Suppurativa Market, Segmentation By Skin Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Hidradenitis Suppurativa Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Hidradenitis Suppurativa Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hidradenitis Suppurativa Market

• 22.1. Russia Hidradenitis Suppurativa Market, Segmentation By Skin Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Hidradenitis Suppurativa Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Hidradenitis Suppurativa Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hidradenitis Suppurativa Market

• 23.1. North America Hidradenitis Suppurativa Market Overview
• 23.2. North America Hidradenitis Suppurativa Market, Segmentation By Skin Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Hidradenitis Suppurativa Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Hidradenitis Suppurativa Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hidradenitis Suppurativa Market

• 24.1. USA Hidradenitis Suppurativa Market Overview
• 24.2. USA Hidradenitis Suppurativa Market, Segmentation By Skin Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Hidradenitis Suppurativa Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Hidradenitis Suppurativa Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hidradenitis Suppurativa Market

• 25.1. Canada Hidradenitis Suppurativa Market Overview
• 25.2. Canada Hidradenitis Suppurativa Market, Segmentation By Skin Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Hidradenitis Suppurativa Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Hidradenitis Suppurativa Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hidradenitis Suppurativa Market

• 26.1. South America Hidradenitis Suppurativa Market Overview
• 26.2. South America Hidradenitis Suppurativa Market, Segmentation By Skin Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Hidradenitis Suppurativa Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Hidradenitis Suppurativa Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hidradenitis Suppurativa Market

• 27.1. Brazil Hidradenitis Suppurativa Market, Segmentation By Skin Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Hidradenitis Suppurativa Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Hidradenitis Suppurativa Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hidradenitis Suppurativa Market

• 28.1. Middle East Hidradenitis Suppurativa Market Overview
• 28.2. Middle East Hidradenitis Suppurativa Market, Segmentation By Skin Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Hidradenitis Suppurativa Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Hidradenitis Suppurativa Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hidradenitis Suppurativa Market

• 29.1. Africa Hidradenitis Suppurativa Market Overview
• 29.2. Africa Hidradenitis Suppurativa Market, Segmentation By Skin Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Hidradenitis Suppurativa Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Hidradenitis Suppurativa Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hidradenitis Suppurativa Market Competitive Landscape And Company Profiles

• 30.1. Hidradenitis Suppurativa Market Competitive Landscape
• 30.2. Hidradenitis Suppurativa Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Eli Lilly and Co Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Hidradenitis Suppurativa Market Other Major And Innovative Companies

• 31.1. UCB S.A.
• 31.2. Leo Pharma A/S
• 31.3. Almirall S.A.
• 31.4. Acelyrin Inc.
• 31.5. AnaptysBio Inc.
• 31.6. Arcutis Biotherapeutics Inc.
• 31.7. Otsuka Pharmaceutical Co. Ltd.
• 31.8. Yamo Pharmaceuticals
• 31.9. Bayer AG
• 31.10. AstraZeneca plc
• 31.11. Sun Pharmaceutical Industries Ltd.
• 31.12. Aurobindo Pharma
• 31.13. Chemocentryx
• 31.14. Priovant Therapeutics
• 31.15. Aristea Therapeutics

32. Global Hidradenitis Suppurativa Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hidradenitis Suppurativa Market

34. Recent Developments In The Hidradenitis Suppurativa Market

35. Hidradenitis Suppurativa Market High Potential Countries, Segments and Strategies

• 35.1 Hidradenitis Suppurativa Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Hidradenitis Suppurativa Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Hidradenitis Suppurativa Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer